Cyclic somatostatin
Based on 1 Customer Validation
Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 38916-34-6
- Formula: C76H104N18O19S2
- Molecular Weight:1637.88
-
Storage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Endogenous Metabolite Isoforms
More
Biological Activity
IC50: 13 nM (contractile response of isoprenaline)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| AtT20 | IC50 |
7.4 x 10-11 M
Compound: Somatostatin-14
|
Displacement of [125I]Tyr11-somatostatin-14 from somatostatin receptor in mouse AtT20 cells
Displacement of [125I]Tyr11-somatostatin-14 from somatostatin receptor in mouse AtT20 cells
|
[PMID: 26988801] |
| AtT20 | IC50 |
7.4 x 10-11 M
Compound: Somatostatin-14
|
Displacement of [125I]Tyr11-somatostatin-14 from Sst receptor in mouse AtT-20 cells measured after 60 mins by scintillation counting method
Displacement of [125I]Tyr11-somatostatin-14 from Sst receptor in mouse AtT-20 cells measured after 60 mins by scintillation counting method
|
[PMID: 27876250] |
| AtT20 | IC50 |
1.3 μM
Compound: 1
|
Compound was tested for its binding affinity against somatostatin receptors on AtT-20 cells
Compound was tested for its binding affinity against somatostatin receptors on AtT-20 cells
|
10.1016/S0960-894X(01)80435-2 |
| CHO | IC50 |
1.6 nM
Compound: 1, Somatostatin, SRIF
|
Displacement of 125I-[LTT]-SRIF-28 from human sst1 receptor in CHO cells after 2 hrs by autoradiography
Displacement of 125I-[LTT]-SRIF-28 from human sst1 receptor in CHO cells after 2 hrs by autoradiography
|
[PMID: 21806016] |
| CHO | IC50 |
1.9 nM
Compound: SS14
|
Displacement of [125I]-[LTT]-SS28 from human SST1 receptor expressed in CHO cells after 2 hrs by autoradiographic analysis
Displacement of [125I]-[LTT]-SS28 from human SST1 receptor expressed in CHO cells after 2 hrs by autoradiographic analysis
|
[PMID: 24378707] |
| CHO-K1 | EC50 |
0.1 nM
Compound: SRIF-14
|
Inhibition of forskolin-induced cAMP accumulation in CHO-K1 cells expressing human sst2 receptor
Inhibition of forskolin-induced cAMP accumulation in CHO-K1 cells expressing human sst2 receptor
|
[PMID: 15982879] |
| CHO-K1 | EC50 |
0.19 nM
Compound: SRIF-14
|
Inhibition of forskolin-induced cAMP accumulation in CHO-K1 cells expressing human sst5 receptor
Inhibition of forskolin-induced cAMP accumulation in CHO-K1 cells expressing human sst5 receptor
|
[PMID: 15982879] |
| CHO-K1 | IC50 |
0.2 nM
Compound: SS-14
|
Inhibitory concentration against human somatostatin receptor type 5 in CHO-K1 cells
Inhibitory concentration against human somatostatin receptor type 5 in CHO-K1 cells
|
[PMID: 16220980] |
| CHO-K1 | IC50 |
0.4 nM
Compound: SS-14
|
Inhibitory concentration against human somatostatin receptor type 3 in CHO-K1 cells
Inhibitory concentration against human somatostatin receptor type 3 in CHO-K1 cells
|
[PMID: 16220980] |
| HEK293 | IC50 |
4.2 nM
Compound: 1, Somatostatin, SRIF
|
Displacement of 125I-[LTT]-SRIF-28 from human sst5 receptor in HEK293 cells after 2 hrs by autoradiography
Displacement of 125I-[LTT]-SRIF-28 from human sst5 receptor in HEK293 cells after 2 hrs by autoradiography
|
[PMID: 21806016] |
| HEK293 | IC50 |
4.2 nM
Compound: SS14
|
Displacement of [125I]-[LTT]-SS28 from human SST5 receptor expressed in HEK293 cells after 2 hrs by autoradiographic analysis
Displacement of [125I]-[LTT]-SS28 from human SST5 receptor expressed in HEK293 cells after 2 hrs by autoradiographic analysis
|
[PMID: 24378707] |
| Pituitary gland cell | IC50 |
0.1 nM
Compound: SS-14
|
Inhibitory concentration on GH release from rat pituitary cells
Inhibitory concentration on GH release from rat pituitary cells
|
[PMID: 16220980] |
| Pituitary gland cell | IC50 |
0.2 nM
Compound: SS-14
|
Inhibitory concentration on PRL release from rat pituitary cells
Inhibitory concentration on PRL release from rat pituitary cells
|
[PMID: 16220980] |
| Pituitary gland cell | IC50 |
0.52 nM
Compound: somatostatin, SRIF[1-14]
|
Tested for inhibition of growth hormone (GH)release from primary cultures of male rat anterior pituitary cells
Tested for inhibition of growth hormone (GH)release from primary cultures of male rat anterior pituitary cells
|
[PMID: 9216843] |
Cyclic somatostatin (0-10 μM; 15 min) dose-dependently inhibits the contractile response to isoprenaline in rat ventricular cardiomyocytes with an IC50 value of 13 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Polypay sheeps[3]
-
Dosage:5 μg/kg
-
Administration:Intravenous injection; 5 μg/kg per hour once; for 18-22 hours
-
Result:Decreased net portal-drained viscera release of glucose, a-amino N, ammonia N, b-hydrox ybutyrate, oxygen consumption, liver oxygen consumption, and total splanchnic a-amino N release and oxygen consumption. Increased lactate release and net hepatic glucose output.
Chemical Information
-
CAS No. 38916-34-6
-
Appearance Solid
-
Molecular Weight 1637.88
-
Formula C76H104N18O19S2
-
Color White to off-white
-
Synonyms
SRIF-14; Somatostatin-14
-
Sequence
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (Disulfide bridge: Cys3-Cys14)
-
Sequence Shortening
AGCKNFFWKTFTSC (Disulfide bridge: Cys3-Cys14)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
Solvent & Solubility
H2O : 100 mg/mL (61.05 mM; Need ultrasonic)
DMF : 100 mg/mL (61.05 mM; Need ultrasonic)
DMSO : ≥ 50 mg/mL (30.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (1.53 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (289 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Murray F, et al. Positive and negative contractile effects of somatostatin-14 on rat ventricular cardiomyocytes. J Cardiovasc Pharmacol. 2001 Mar;37(3):324-32. [Content Brief]
[2]. Bell D, et al. SRIF receptor subtype expression and involvement in positive and negative contractile effects of somatostatin-14 (SRIF-14) in ventricular cardiomyocytes. Cell Physiol Biochem. 2008;22(5-6):653-64. [Content Brief]
[3]. McLeod KR, et al. Effects of exogenous somatostatin and cysteamine on net nutrient flux across the portal-drained viscera and liver of sheep during intraduodenal infusion of starch hydrolysate and casein. J Anim Sci. 1997 Nov;75(11):3026-37. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O / DMF | 1 mM | 0.6105 mL | 3.0527 mL | 6.1055 mL | 15.2636 mL |
| 5 mM | 0.1221 mL | 0.6105 mL | 1.2211 mL | 3.0527 mL | |
| 10 mM | 0.0611 mL | 0.3053 mL | 0.6105 mL | 1.5264 mL | |
| 15 mM | 0.0407 mL | 0.2035 mL | 0.4070 mL | 1.0176 mL | |
| 20 mM | 0.0305 mL | 0.1526 mL | 0.3053 mL | 0.7632 mL | |
| 25 mM | 0.0244 mL | 0.1221 mL | 0.2442 mL | 0.6105 mL | |
| 30 mM | 0.0204 mL | 0.1018 mL | 0.2035 mL | 0.5088 mL | |
| H2O / DMF | 40 mM | 0.0153 mL | 0.0763 mL | 0.1526 mL | 0.3816 mL |
| 50 mM | 0.0122 mL | 0.0611 mL | 0.1221 mL | 0.3053 mL | |
| 60 mM | 0.0102 mL | 0.0509 mL | 0.1018 mL | 0.2544 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cyclic somatostatin Related Classifications
HY-P0084 Related Classifications
Powered by Bioz